The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in Description. Co-administration with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein transporter (P-gp) and thus may lead to lower exposure and loss of efficacy of Daclatasvir. These active substances include but are not limited to phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John's wort (Hypericum perforatum).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
